Richard joined the MHRA as a GMP Inspector in 2001 and is currently a Unit Manager with responsibility for the GMP and GPvP Inspection teams. Prior to joining the MHRA Richard worked in the pharmaceutical industry for over 17 years focusing mainly on the manufacture of bulk active pharmaceutical ingredients. He has experience of process development and technical support and has held managerial positions in both QA and production. Whilst at the MHRA, in addition to the inspection of a wide range of pharmaceutical manufacturers, Richard has been an Operations Manager with responsibility for teams of both GMP and GDP Inspectors and has most recently been part of the Agency team responsible for implementing the changes arising from the Falsified Medicines Directive.

Mark joined the MHRA in 2002 and is currently the Group Manager for the Inspectorate which comprises of over 80 Inspectors. Mark is a chemistry graduate with an MSc in pharmaceutical sciences. He previously worked in the pharmaceutical industry for over 10 years in a variety of roles including process technology, new product introduction and quality assurance and he is eligible to be named as a Qualified Person under Directive 2001/83/EC.

Ian White joined the MHRA as a GMDP Inspector in 2016 having worked within pharmaceutical and biotech industries for over 15 years.

During this time he held managerial roles in Production, Quality Control and Quality Assurance working across a diverse product portfolio, ranging from biologics to traditional herbal medicines and incorporating a wide range of dosage forms.

Kevin has been with the MHRA GMP Inspectorate since March 2016.  Before joining the MHRA he worked in the pharmaceutical industry for over 17 years. His roles included QC, validation and QA operations management.  He has worked on projects including transferring products between sites, commissioning of a new site, facility upgrades, introducing MES, data historian and site process control systems.  He has knowledge of a variety of dosage forms and is a Chartered Chemist.

Graham has been a GMDP Operations Manager since 2017 and a GMDP Inspector since joining the MHRA in 2013. He is a Mechanical Engineer (MEng) by training. Prior to joining the MHRA Graham spent eight years working in the pharmaceutical industry in the areas of human plasma fractionation and sterile product manufacturing; this included operational and managerial roles in Validation and Quality Assurance. Graham specialises in the inspection of sterile product manufacture as well as the collection, processing and supply of blood and blood components.

David has been a GMDP inspector with the UK Medicines and Healthcare Products Regulatory Agency since 2004 with responsibility for leading inspections of pharmaceutical manufacturers and blood establishments in the UK and internationally. In his current role, David is the MHRA representative at the EMA Inspectors Working Group, and other EU and international groups to develop and revise GMP regulations and standards. David leads the agency team responsible for delivering data integrity inspection strategy and training, and is co-chair of the PIC/S data integrity working group. Prior to joining the MHRA, he was a Principal Pharmacist and production manager in the UK's National Health Service, responsible for the manufacture of aseptically prepared radioactive diagnostic agents, chemotherapy and parenteral nutrition products.

Andy has been with the MHRA since March 2005 as a GMP Inspector. He became a Senior GMP Inspector 2009 and an Expert GMDP Inspector in 2015.

Tracy has been with the MHRA GMP Inspectorate since 2011 and before joining the MHRA worked in the pharmaceutical industry for over 23 years. She worked across all dosage forms within Quality roles and is eligible to act as a Qualified Person under 2001/83. Tracy is the lead for the Agency team responsible for delivering data integrity strategy and training. 

Trevor has been a GMDP Inspector with the MHRA since 2014. In his role he inspects manufacturers, importers and wholesalers in the UK, and manufacturing sites in third countries.

Prior to joining MHRA, Trevor worked in the UK pharmaceutical industry for over 25 years, in a variety of Quality Control and Quality Assurance roles. He is eligible to be named as a Qualified Person under the permanent provisions of Directive 2001/83/EC, and is a chemist by degree.

Peter joined the MHRA in 1993, having spent the previous three years with the Department of Health and NHS Management Executive in Leeds. Peter initially worked in the Enforcement Group and was responsible for conducting a two-year project into the use of Traditional Chinese Medicines in the UK before managing the unit's criminal prosecution team. Peter joined the GDP Inspectorate in June 2002 and became an Operations Manager in November 2011 and a Senior Inspector in 2016. Peter currently leads one of the GDP Inspectorates two operational teams and combines this role with being a member of the GDP Inspectorates Senior Inspector Group.  

Bernadette is a GDP Inspector and joined the MHRA in March 2005.  Her previous experience includes local government enforcement duties within a Trading Standards environment.  Bernadette spent 10 years working as an Investigator within the MHRA Enforcement and Intelligence division dealing with criminal investigations.  She has played an important role in the year on year success of the MHRA's Operation Pangea which focuses on the illegal internet trade of medicines and medical devices globally.  In 2015, £15.8 million worth of fake medicines and devices were seized during UK operations.  Bernadette is an accredited Counter Fraud Specialist.

Cheryl joined the MHRA as a GDP inspector in 2005. Cheryl is a Chartered Chemist and spent many years working within industry as a research chemist during which time she filed a number of patents both European and Worldwide. She has extensive experience working within Project and Programme Management roles with responsibility for a wide range of projects spanning various scientific and engineering disciplines. As well a performing a full range of GDP inspections nationwide, Cheryl was the MHRA representative on the GDP drafting Group at the EMA. Since the current guidance has been implemented, Cheryl has been leading the project to raise awareness within the medicines supply chain that companies and sites not previously regulated are impacted by the change in legislation.

Claire joined the agency as a GDP Inspector in January 2013 and has a background in pharmaceutical manufacturing and auditing of 15 years. Aspects of previous roles in a large pharmaceutical company include project management, QMS implementation and Quality Assurance. She is PRINCE2 qualified and has a degree in Business.

Terry is an Inspector within the GDP Inspectorate at the Medicines and Healthcare products Regulatory Agency (MHRA). He joined the Agency in 2009 having previously worked over 25 years in a variety of pharmaceutical industry technical and managerial roles within R&D and QA.

Tony was a founder member of the GDP Inspectorate when it was created in 2001 and is a Senior GDP Inspector responsible for inspecting the full range of UK distribution companies. He is a member of the PIC/S GDP working group, working on the training and aligning of GDP standards for PIC/S member countries. He was part of the EMA GDP drafting group preparing the GDP Guidelines and updates to the compilation of community procedures and involved in training the GMDP inspectors on the new guidelines. He was also a member of the team who reviewed the UK supply chain and looked at ways to improve the standard of the Wholesale Dealer 'Responsible Person'. He is currently a member of the implementation team for the Falsified Medicines Directive and working on developing the new Risk Based Inspection IT system for the MHRA. Tony has been with the MHRA for 24 years, working initially with the MHRA Enforcement Group where he was a Senior Investigation Officer. As such he was responsible for investigating counterfeit medicines, internet sales and other illegal activity with pharmaceuticals.

Madeleine is a senior GDP inspector and joined the MHRA in August 2009 becoming a senior inspector in 2015. Her previous experience includes NHS pharmacy manufacturing, project management in NHS Blood and Transplant and some teaching within the NHS. Recent projects include working with Cogent to develop the Cogent approval process for RP courses following the successful work on the RP Gold Standard; and working with the Maritime and Coastguard Agency to improve compliance within the marine sector. Madeleine enjoys contributing to inspector development, inspection consistency and wholesaler compliance through shared working with enforcement and the Inspection Action Group. Madeleine is educated to masters level with an MBA, BA Honours Degree, Post-graduate Certificate in Education, and a Postgraduate Diploma in Project Management in addition to PRINCE2.

Peter is a pharmacist by profession and joined the MHRA in January 2013. Prior to joining the MHRA, Peter had worked in the pharmaceutical industry for over 30 years, focusing mainly on Pharmaceutical Wholesale and Retail Pharmacy.in various managerial roles including Operations Management, Regulatory Affairs, Quality Assurance and acted as Responsible Person for a number of companies in the UK. He was an industry representative on the HDA UK (BAPW) RP Committee, was instrumental in identifying some of the more recent examples of falsified medicines and is a member of the MHRA Falsified Medical Product Stakeholders Group.

More recently he has been involved in a number of meetings and working groups involved in the implementation of the Falsified Medicines Directive in the UK.

Gaynor joined the MHRA as a GDP Inspector in May 2009 formally working in the pharmaceutical wholesale distribution industry for over 10 years as a Project Manager and Business Compliance Manager. Her roles included auditing the organisation to ensure legal compliance with regulatory bodies including compliance to GDP. Gaynor was also involved in a number of large projects including the management of a building project and the implementation of automation in a large distribution site. She has qualifications in Project Management and Health and Safety. Gaynor spent two years as the MHRA's Health and Safety Manager achieving BS18001 certification. She returned to her GDP Inspector role in July 2013.

Alan Bentley joined the MHRA in November 2006, working initially in the British Pharmacopoeia Secretariat developing technical standards for biologicals and antibiotics. Between 2009 and 2012 he worked in the Inspection, Enforcement & Standards Division's Regulatory Advice Unit, providing advice to manufacturers & wholesale dealers and contributing to the review of the Medicines Act & UK implementation of the Falsified Medicines Directive (2011/62/EU). He moved to the GDP Inspectorate in September 2012. Prior to joining the MHRA he had gained 15 years' experience in the pharmaceutical industry in a variety of roles, from pre-clinical research through to full scale manufacture.